Biblio

Export 751 results:
Author Title Type Year
Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Peptide Fragments
M. Fà, Zhang, H., Staniszewski, A., Saeed, F., Shen, L. W., Schiefer, I. T., Siklos, M. I., Tapadar, S., Litosh, V. A., Libien, J., Petukhov, P. A., Teich, A. F., Thatcher, G. R. J., and Arancio, O., “Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 707-21, 2016.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
S. Tholen, Schmaderer, C., Chmielewski, S., Förstl, H., Heemann, U., Baumann, M., Steubl, D., and Grimmer, T., “Reduction of Amyloid-β Plasma Levels by Hemodialysis: An Anti-Amyloid Treatment Strategy?”, J Alzheimers Dis, vol. 50, no. 3, pp. 791-6, 2016.
J. Bennett, Burns, J., Welch, P., and Bothwell, R., “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
D. A. Nation, Ho, J., and Yew, B., “Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.”, J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
H. Jin, Chen, T., Li, G., Wang, C., Zhang, B., Cao, X., Sha, S., Wan, Q., and Chen, L., “Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of Aβ 1-42.”, J Alzheimers Dis, vol. 50, no. 2, pp. 501-16, 2016.
Z. - Q. Xu, Huang, H., Chen, Y. - L., Gao, Y. - Y., Xu, J., Marshall, C., Cai, Z. - Y., and Xiao, M., “Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 179-95, 2016.
C. Huang, Ng, O. Tsz- Wa, Ho, Y. - S., Irwin, M. Garnet, Chang, R. Chuen- Chun, and Wong, G. Tin- Chun, “Effect of Continuous Propofol Infusion in Rat on Tau Phosphorylation with or without Temperature Control.”, J Alzheimers Dis, vol. 51, no. 1, pp. 213-26, 2016.
T. Porter, Bharadwaj, P., Groth, D., Paxman, A., Laws, S. M., Martins, R. N., and Verdile, G., “The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity.”, J Alzheimers Dis, vol. 50, no. 3, pp. 895-905, 2016.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
L. Chang, Zhang, Y., Liu, J., Song, Y., Lv, A., Li, Y., Zhou, W., Yan, Z., Almeida, O. F. X., and Wu, Y., “Differential Regulation of N-Methyl-D-Aspartate Receptor Subunits is an Early Event in the Actions of Soluble Amyloid-β(1-40) Oligomers on Hippocampal Neurons.”, J Alzheimers Dis, vol. 51, no. 1, pp. 197-212, 2016.
E. Niemantsverdriet, Goossens, J., Struyfs, H., Martin, J. - J., Goeman, J., De Deyn, P. Paul, Vanderstichele, H., and Engelborghs, S., “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
J. A. Luchsinger, Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., and Bagiella, E., “Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.”, J Alzheimers Dis, vol. 51, no. 2, pp. 501-14, 2016.
S. Eketjäll, Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J., Haeberlein, S. Budd, Kugler, A. R., Alexander, R. C., and Cebers, G., “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
K. Krishna, Behnisch, T., and Sajikumar, S., “Inhibition of Histone Deacetylase 3 Restores Amyloid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons.”, J Alzheimers Dis, vol. 51, no. 3, pp. 783-91, 2016.
C. Peters, Bascuñán, D., Opazo, C., and Aguayo, L. G., “Differential Membrane Toxicity of Amyloid-β Fragments by Pore Forming Mechanisms.”, J Alzheimers Dis, vol. 51, no. 3, pp. 689-99, 2016.
M. T. White, Shaw, L. M., and Xie, S. X., “Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 463-70, 2016.
G. Lou, Zhang, Q., Xiao, F., Xiang, Q., Su, Z., and Huang, Y., “Intranasal TAT-haFGF Improves Cognition and Amyloid-β Pathology in an AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 985-90, 2016.
M. Bocchetta, Mega, A., Bernardi, L., Di Maria, E., Benussi, L., Binetti, G., Borroni, B., Colao, R., Di Fede, G., Fostinelli, S., Galimberti, D., Gennarelli, M., Ghidoni, R., Piaceri, I., Pievani, M., Porteri, C., Redaelli, V., Rossi, G., Suardi, S., Babiloni, C., Scarpini, E., Tagliavini, F., Padovani, A., Nacmias, B., Sorbi, S., Frisoni, G. B., and Bruni, A. C., “Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.”, J Alzheimers Dis, vol. 51, no. 1, pp. 277-91, 2016.
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
N. R. Barthélemy, Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., and Lehmann, S., “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
N. Lelental, Brandner, S., Kofanova, O., Blennow, K., Zetterberg, H., Andreasson, U., Engelborghs, S., Mroczko, B., Gabryelewicz, T., Teunissen, C., Mollenhauer, B., Parnetti, L., Chiasserini, D., Molinuevo, J. Luis, Perret-Liaudet, A., Verbeek, M. M., Andreasen, N., Brosseron, F., Bahl, J. M. C., Herukka, S. - K., Hausner, L., Frölich, L., Labonte, A., Poirier, J., Miller, A. - M., Zilka, N., Kovacech, B., Urbani, A., Suardi, S., Oliveira, C., Baldeiras, I., Dubois, B., Rot, U., Lehmann, S., Skinningsrud, A., Betsou, F., Wiltfang, J., Gkatzima, O., Winblad, B., Buchfelder, M., Kornhuber, J., and Lewczuk, P., “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
J. J. Gomar, Conejero-Goldberg, C., Davies, P., and Goldberg, T. E., “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.

Pages